141 related articles for article (PubMed ID: 3840949)
81. Chlorozotocin. Mechanism of reduced bone marrow toxicity in mice.
Panasci LC; Green D; Schein PS
J Clin Invest; 1979 Oct; 64(4):1103-11. PubMed ID: 158033
[TBL] [Abstract][Full Text] [Related]
82. In vitro and in vivo anti-tumor activity of L-glutamic acid gamma-monohydroxamate against L1210 leukemia and B16 melanoma.
Vila J; Thomasset N; Navarro C; Doré JF
Int J Cancer; 1990 Apr; 45(4):737-43. PubMed ID: 2323850
[TBL] [Abstract][Full Text] [Related]
83. [Antitumor activity of new derivatives of camptothecin].
Nitta K; Yokokura T; Sawada S; Kunimoto T; Tanaka T; Uehara N; Baba H; Takeuchi M; Miyasaka T; Mutai M
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):850-7. PubMed ID: 3566296
[TBL] [Abstract][Full Text] [Related]
84. Antitumor activity of pyrindamycins A and B.
Ishii S; Nagasawa M; Kariya Y; Yamamoto H; Inouye S; Kondo S
J Antibiot (Tokyo); 1989 Nov; 42(11):1713-7. PubMed ID: 2531136
[TBL] [Abstract][Full Text] [Related]
85. In vivo antitumor activity and in vitro cytotoxic properties of bis[1,2-bis(diphenylphosphino)ethane]gold(I) chloride.
Berners-Price SJ; Mirabelli CK; Johnson RK; Mattern MR; McCabe FL; Faucette LF; Sung CM; Mong SM; Sadler PJ; Crooke ST
Cancer Res; 1986 Nov; 46(11):5486-93. PubMed ID: 3756897
[TBL] [Abstract][Full Text] [Related]
86. Antitumor effects of gossypol on murine tumors.
Rao PN; Wang YC; Lotzova E; Khan AA; Rao SP; Stephens LC
Cancer Chemother Pharmacol; 1985; 15(1):20-5. PubMed ID: 4006045
[TBL] [Abstract][Full Text] [Related]
87. Axial ligands and alicyclic ring size modulate the activity and biochemical pharmacology of ammine/cycloalkylamine-platinum(IV) complexes in tumor cells resistant to cis-diamminedichloroplatinum(II) or trans-1R,2R-1S,2S-diaminocyclohexanetetrachloroplatinum(IV).
Yoshida M; Khokhar AR; Siddik ZH
Cancer Res; 1994 Sep; 54(17):4691-7. PubMed ID: 8062266
[TBL] [Abstract][Full Text] [Related]
88. Effects of 5-aza-2'-deoxycytidine on survival and cell cycle progression of L1210 leukemia cells.
Chabot GG; Momparler RL
Leuk Res; 1986; 10(5):533-7. PubMed ID: 2423812
[TBL] [Abstract][Full Text] [Related]
89. [Study of new antineoplastic antibiotics based on newly discovered action mechanisms].
Tanaka N
Gan To Kagaku Ryoho; 1983 Apr; 10(4 Pt 2):1094-106. PubMed ID: 6191673
[TBL] [Abstract][Full Text] [Related]
90. Inhibitory activity of diarylamidine derivatives on murine leukemia L1210 cell growth.
Balzarini J; de Clercq E; Dann O
Invest New Drugs; 1983; 1(2):103-15. PubMed ID: 6678860
[TBL] [Abstract][Full Text] [Related]
91. Activity of batracylin (NSC-320846) against solid tumors of mice.
Mucci-LoRusso P; Polin L; Bissery MC; Valeriote F; Plowman J; Luk GD; Corbett TH
Invest New Drugs; 1989 Nov; 7(4):295-306. PubMed ID: 2557298
[TBL] [Abstract][Full Text] [Related]
92. Relationship of reduced folate changes to inhibition of DNA synthesis induced by methotrexate in L1210 cells in vivo.
Priest DG; Bunni M; Sirotnak FM
Cancer Res; 1989 Aug; 49(15):4204-9. PubMed ID: 2743307
[TBL] [Abstract][Full Text] [Related]
93. Enhancement of folate analogue transport inward in L1210 cells during methotrexate therapy of leukemic mice: evidence of the nature of the effect, possible host mediation, and pharmacokinetic significance.
Sirotnak FM; Poser RE; Barrueco JR
Cancer Res; 1987 Oct; 47(20):5334-9. PubMed ID: 3498533
[TBL] [Abstract][Full Text] [Related]
94. Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells.
Keyomarsi K; Moran RG
Cancer Res; 1986 Oct; 46(10):5229-35. PubMed ID: 2944577
[TBL] [Abstract][Full Text] [Related]
95. Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent.
Hendriks HR; Plowman J; Berger DP; Paull KD; Fiebig HH; Fodstad O; Dreef-van der Meulen HC; Henrar RE; Pinedo HM; Schwartsmann G
Ann Oncol; 1992 Nov; 3(9):755-63. PubMed ID: 1450065
[TBL] [Abstract][Full Text] [Related]
96. Drug sensitivity of ten human tumor cell lines compared to mouse leukemia (L1210) cells.
Badiner GJ; Hamilton RD; Li LH; Bhuyan BK
Invest New Drugs; 1987; 5(3):219-29. PubMed ID: 3667160
[TBL] [Abstract][Full Text] [Related]
97. Biochemical pharmacology and antitumor properties of 4-amino-8-[beta-D-ribofuranosylamino]pyrimido-[5,4-d]pyrimidine.
Jackson RC; Boritzki TJ; Cook PD; Hook KE; Leopold WR; Fry DW
Adv Enzyme Regul; 1989; 28():185-99. PubMed ID: 2560325
[TBL] [Abstract][Full Text] [Related]
98. Dezaguanine mesylate: a new antipurine antimetabolite.
Leopold WR; Fry DW; Boritzki TJ; Besserer JA; Pattison IC; Jackson RC
Invest New Drugs; 1985; 3(3):223-31. PubMed ID: 4066218
[TBL] [Abstract][Full Text] [Related]
99. Cytotoxic activity of the selected pyridinium salts against murine leukemia L1210.
Wieczorkowska M; Szajerski P; Michalski R; Adamus J; Marciniak A; Gebicki J; Ciesielska E; Szmigiero L; Lech-Marańda E; Szmigielska-Kapłon A; Robak T
Pharmacol Rep; 2007; 59(2):216-23. PubMed ID: 17556800
[TBL] [Abstract][Full Text] [Related]
100. Total synthesis and evaluation of cytostatin, its C10-C11 diastereomers, and additional key analogues: impact on PP2A inhibition.
Lawhorn BG; Boga SB; Wolkenberg SE; Colby DA; Gauss CM; Swingle MR; Amable L; Honkanen RE; Boger DL
J Am Chem Soc; 2006 Dec; 128(51):16720-32. PubMed ID: 17177422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
